Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2 Clinical Trial of Neoadjuvant Pembrolizumab Plus Concurrent Chemoradiotherapy With Weekly Carboplatin and Paclitaxel in Adult Patients With Resectable, Locally Advanced Adenocarcinoma of the Gastroesophageal Junction or Gastric Cardia

NCT02730546 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT02730546
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02730546 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2 Clinical Trial of Neoadjuvant Pembrolizumab Plus Concurrent Chemoradiotherapy With Weekly Carboplatin and Paclitaxel in Adult Patients With Resectable, Locally Advanced Adenocarcinoma of the Gastroesophageal Junction or Gastric Cardia
Lead sponsor
Mayo Clinic
Phase
Phase 1/2
Overall status
Completed
Start date
June 24, 2016
Completion date
October 31, 2023
Enrollment
31 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cardia adenocarcinoma, gastroesophageal junction adenocarcinoma, stage ib gastric cancer ajcc v7, stage ii gastric cancer ajcc v7, stage iia gastric cancer ajcc v7, stage iib gastric cancer ajcc v7, stage iiia gastric cancer ajcc v7, stage iiib gastric cancer ajcc v7